How National Health Insurance Coverage Policy Affected the Use of Trastuzumab and Rituximab in China: A Bicentric Retrospective Study.

Shang, Linlin; Lin, Yingtao; Fang, Wenqing; Liu, Yanyan; Bao, Yuwen; Li, Xin; Zhang, Yuanyuan

Shang, Linlin; Lin, Yingtao; Fang, Wenqing; Liu, Yanyan; Bao, Yuwen; Li, Xin; Zhang, Yuanyuan.

Afiliação

Shang L; Department of Clinical Pharmacy, School of Pharmacy, Nanjing Medical University, Nanjing, People's Republic of China.
Lin Y; Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, People's Republic of China.
Fang W; Department of Medical Ethics Supervision, The First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China.
Liu Y; Department of Health Policy, School of Health Policy and Management, Nanjing Medical University, Nanjing, People's Republic of China.
Bao Y; Department of Health Policy, School of Health Policy and Management, Nanjing Medical University, Nanjing, People's Republic of China.
Li X; Department of Clinical Pharmacy, School of Pharmacy, Nanjing Medical University, Nanjing, People's Republic of China.
Zhang Y; Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, People's Republic of China.

Risk Manag Healthc Policy ; 16: 1739-1753, 2023.

Article em En | MEDLINE | ID: mdl-37692767

Palavras-chave

National Health Insurance Coverage; breast cancer; non-Hodgkin lymphoma; rituximab; trastuzumab; utilization

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Observational_studies Idioma: En Revista: Risk Manag Healthc Policy Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google